A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals

Graeme J. Moyle, Chloe Orkin, Martin Fisher, Jyoti Dhar, Jane Anderson, Edmund Wilkins, Jacqueline Ewan, Ramin Ebrahimi, Hui Wang, J. Ainsworth, A. Waters, L. Morumba, G. Brook, M. Chikohora, P. Hay, A. Adebiyi, M. Cockerill, M. Ndoro, M. Johnson, A. CarrollF. Turner, G. Moyle, C. Fletcher, J. Osorio, C. Orkin, J. Hand, C. Desouza, M. Fisher, N. Perry, T. Maher, A. Bray, A. De Burgh Thomas, M. Bunting, L. Jones, D. White, J. Groves, J. Ross, L. Brown, K. Hood, J. Dhar, S. Johnson, E. Morgan, R. Hewart, E. Ong, E. Wilkins, E. Stockwell, A. Robertson, C. Leen, S. Morris, L. Ellis, R. Maw, S. McKernan, D. C. Herath, J. Ewan, M. Hui Wang, R. Ebrahimi

    Research output: Contribution to journalArticlepeer-review

    26 Citations (Scopus)
    Original languageEnglish
    Article numbere0116297
    JournalPLoS ONE
    Volume10
    Issue number2
    DOIs
    Publication statusPublished (VoR) - 6 Feb 2015

    Fingerprint

    Dive into the research topics of 'A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals'. Together they form a unique fingerprint.

    Cite this